San Diego, Calif. October 1, 2025 – Primrose Bio, Inc. (“Primrose”) announced today the appointment of Andrew “Drew” Burch as its Chief Executive Officer, and member of the Board of Directors. Drew succeeds Helge Zieler, PhD, who will move into a new role of Chief...

Significantly increased quality and lower manufacturing costs for long template mRNAs San Diego, Calif. March 26, 2025 – Primrose Bio, Inc. (“Primrose”), a company developing proprietary therapeutic manufacturing technologies, announces the launch of Prima RNApols™...

Primrose Bio, Inc. (“Primrose”), a company with proprietary manufacturing technologies for human therapeutics, and Serum Institute of India Pvt. Ltd. (“SIIPL”), the world’s largest vaccine manufacturer, today announced a collaboration to develop a novel multi-antigen...

Primrose Bio, a leading biotechnology company specializing in technologies that improve the manufacturing of next-generation therapeutics, and ExPLoRNA Therapeutics, a pioneering biotechnology company advancing mRNA technologies, vaccines, and therapeutics, announced...

Primrose Bio, Inc. (“Primrose,” the “Company”), a company focused on developing and licensing its manufacturing technologies for nucleic acids and proteins used in therapeutics and vaccines, announced a significant equity investment from 1315 Capital, a...

The companies will leverage their combined experience in the development of conjugate vaccines for their clients  Primrose Bio will supply its industry-leading carrier protein, PeliCRM197®, for vaccine development Intravacc has IP and know how in vaccine...